Abstract
The goal of this study was to evaluate the efficacy of CA-125 area under the curve (CA-125 AUC) as a prognostic factor following surgical treatment for ovarian cancer patients. A retrospective analysis was conducted on ninety-five patients with ovarian cancer who had primary treatment in a tertiary center between 2000 and 2010. After either optimal or cytoreductive surgery, all patients underwent adjuvant chemotherapy. CA-125 AUC was calculated for each patient that had a minimum of three CA-125 serum measurements during the treatment period. The mean age at diagnosis and mean survival were 53.9 years (range, 16–75 years) and 35.6 ± 22.9 months (range, 3.1–95.4 months), respectively. The mean (and median) CA-125 AUC of patients of FIGO stages I, II, III, and IV was 53.0 (42.5), 58.06 (58.06), 97.8 (54.6), and 405.2 (149.3) IU/ml day, respectively (p = 0.004). The mean CA-125 AUC was 57.7, 410.1, and 636.3 IU/ml day for patients with a complete response, partial response, and no response/progressive disease to first-line chemotherapy, respectively (p < 0.001). The CA-125 AUC cut-off level for an overall survival of ≥5 years was 99.75 IU/ml day with a sensitivity of 90.9 % (95 % CI, 70.8–98.6) with 1.27 as positive likelihood ratio. Patients who suffer from ovarian cancer, with a lower CA125 AUC, have a better overall survival than those with a higher CA125 AUC. CA-125 AUC could be used as an independent factor for evaluating the treatment efficacy and chemotherapy response.
Similar content being viewed by others
References
Baker VV. Treatment options for ovarian cancer. Clin Obstet Gynecol. 2001;44:522–30.
Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin. 1999;49:297–320.
Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998;13:179–87.
Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992;79:1002–10.
Bidart JM, Thuillier F, Augereau C, et al. Kinetics of serum marker concentrations and usefulness in clinical monitoring. Clin Chem. 1999;45:1695–707.
Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.
Mano A, Falcão A, Godinho I, et al. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol. 2005;97:529–34.
Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol. 1991;165:360–7.
Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. Serum CA 125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol. 1992;47:87–92.
Fayers PM, Rusting G, Wood R, et al. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the medical research council working party on gynaecological cancer. Int J Gynecol Cancer. 1993;3:285–92.
Gadducci A, Zola P, Landoni F, et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol. 1995;58:42–7.
van der Burg ME, Lammes FB, van Putten WL, Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol. 1988;30:307–12.
Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1989;96:1395–9.
Hunter VJ, Daly L, Helms M, et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received chemotherapy after surgical cytoreduction. Am J Obstet Gynecol. 1990;163:1164–7.
Colaković S, Lukiç V, Mitroviç L, Jeliç S, Susnjar S, Marinkoviç J. Prognostic value of CA 125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers. 2000;15:147–52.
Gupta D, Lammersfeld AC, Vashi PG, Braun DP. Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer. J Ovarian res. 2010;3:22.
Markman M, Federico M, Liu PY, Hannigan E, Alberts D. Significance of early changes in the serum CA125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol. 2006;103:195–8.
Riedinger JM, Bnnetain F, Basuyau JP, et al. Change in CA125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol. 2007;18:881–5.
Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–63.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Uzunoglu, S., Aybatlı, A., Kaplan, P.B. et al. Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer. Med Oncol 30, 447 (2013). https://doi.org/10.1007/s12032-012-0447-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-012-0447-x